CHRONIC LYMPHOCYTIC LEUKAEMIA
Clinical trials for CHRONIC LYMPHOCYTIC LEUKAEMIA explained in plain language.
Never miss a new study
Get alerted when new CHRONIC LYMPHOCYTIC LEUKAEMIA trials appear
Sign up with your email to follow new studies for CHRONIC LYMPHOCYTIC LEUKAEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for leukemia patients with weak hearts: safer drug trial launches
Disease control Recruiting nowThis study compares a targeted drug called acalabrutinib to other standard treatments for adults with chronic lymphocytic leukemia (CLL) who also have moderate to severe heart failure. The main goal is to see if acalabrutinib causes fewer heart-related side effects. About 60 part…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKAEMIA
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 16, 2026 23:36 UTC
-
New drug AZD0486 shows promise in early trial for blood cancers
Disease control Recruiting nowThis study is testing a new drug called AZD0486, either by itself or with other cancer treatments, in people with certain types of blood cancers like chronic lymphocytic leukemia and lymphoma. The main goals are to check if the drug is safe and to find the best dose. About 408 pa…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKAEMIA
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 16, 2026 23:31 UTC
-
New pill shows promise against tough blood cancers
Disease control Recruiting nowThis study tests an oral drug called MK-1026 (nemtabrutinib) in about 490 people with certain blood cancers, including chronic lymphocytic leukemia, non-Hodgkin lymphoma, and Waldenström's macroglobulinemia. The main goals are to check safety and see how well the drug shrinks or …
Matched conditions: CHRONIC LYMPHOCYTIC LEUKAEMIA
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Gene therapy Follow-Up: did the treatment leave a mark in new cancers?
Knowledge-focused Recruiting nowThis study looks at tumor samples from 50 people who received a Bristol-Myers Squibb gene-modified cell therapy for blood cancers like lymphoma or myeloma and later developed a second cancer. Researchers will test these samples to see if any therapy-related genes are present. The…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKAEMIA
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC